Synagis' Special Status Under Health Care Reform
This article was originally published in The Pink Sheet Daily
The new Medicaid rebate rules don't bite as deeply for drugs approved exclusively for pediatric use. It turns out that AstraZeneca/MedImmune's Synagis is the only therapy to qualify.
You may also be interested in...
Big Pharma's first quarter earnings reports offered the first estimates of the impact from health care reform on the industry. Wall Street was taken aback at the size of some of the hits. But not everyone is equally affected-nor will everyone be feeling the same burden when new impacts begin in 2011.
The Biden Administration’s signature health research agency ARPA-H is still in the formative stages. Authorizing legislation moving through Congress could set up a very interesting dynamic when it comes to working with the US FDA.
US FDA’s push to re-think oncology dosing should begin by renaming the initial human trials to de-emphasize toxicity, a National Cancer Institute official suggests.